-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on BioCryst Pharma, Maintains $15 Price Target

Benzinga·04/10/2025 11:07:53
Listen to the news
Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $15 price target.